ARCHIVED: Appendix 4: The Management of the National Antiviral Stockpile: Options Report - Comparison of international stockpiling tends
Country (population) |
Size and composition of stockpile | Uses | Comment |
---|---|---|---|
Canada (33M) |
~ 25% of population NAS: |
Early treatment, Rapid containment Outbreak control; Post-exposure prophylaxis in Phase 4/5 | Private stockpiles may be present for pre-exposure prophylaxis |
United States (304M) |
25% of population (Goal 35%) almost all oseltamivir |
Early treatment, rapid containment (prophylaxis to be covered by private stockpiling) | Endorsing private stockpiling; has well-established shelf-life extension program |
United Kingdom (61M) |
25% population; recent commitment to increase to 50% population (32.8M) - two thirds oseltamivir |
Early treatment – enough for severe pandemic and small amount for pre exposure prophylaxis | Post-exposure prophylaxis in households under consideration; looking at alternatives for expiring stock |
France (62M) |
50% of population (may share with other EU countries) - 240 M doses oseltamivir |
Early treatment; pre-exposure prophylaxis in Phase 4/5 | Stock began to expire in 2008; looking at shelf-life extension |
Japan (127M) |
23% of population, target is 45% (may share with Thailand and other Asian countries) - 240M doses oseltamivir |
Largely early treatment | Has a shelf-life extension program |
Source: Global Health Security Action Group Pandemic Influenza Planning and Preparedness Survey, 2008
Page details
- Date modified: